[Another testimony amidst schools].

Perspect Infirm

Published: March 2012

Download full-text PDF

Source

Publication Analysis

Top Keywords

[another testimony
4
testimony amidst
4
amidst schools]
4
[another
1
amidst
1
schools]
1

Similar Publications

Introduction: Preventing depression among nurses is a critical issue from the perspective of occupational welfare, but associations between depressive symptoms in nurses and stress-coping strategies remain unclear.

Methods: In the present study, an epidemiological study was conducted based on a cross-sectional questionnaire survey. Data obtained from 2,534 female nurses working at three general hospitals in Tokyo, Japan, were analyzed.

View Article and Find Full Text PDF

Objectives: The objective is to compare the learning curves between two pioneer and three second-generation surgeons for RAPN in terms of WIT, CD and positive surgical margins.

Materials And Methods: The charts of consecutive RAPNs of three centres were reviewed from the UroCCR prospective database. The experience was assessed by a regression model for each group.

View Article and Find Full Text PDF

Background: "Before medically advised" (BMA) discharges are rising among hospitalized people with opioid use disorder (OUD) and associated with worse outcomes. However, little is known about BMA discharge among the growing share of U.S.

View Article and Find Full Text PDF

Calcium (Ca) is necessary for bone health and metabolic functions in poultry, however, the extent to which it can be utilized varies among feed ingredients. The goal of this study was to determine the apparent ileal digestibility (AID) and standardized ileal digestibility (SID) of calcium in wheat and soybean meal (SBM) in young quail chicks using a direct method. Three dietary treatments were used in the experiment: a calcium-free basal diet to determine endogenous calcium losses, and two diets with either wheat or SBM as the primary calcium sources.

View Article and Find Full Text PDF

Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!